Nichi-Iko Pharmaceut (NHKFF) 18.2500 $NHKFF Nic
Post# of 273254
Posted On: 09/22/2016 7:18:58 AM
Nichi-Iko Pharmaceut (NHKFF) 18.2500 $NHKFF
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 29, 6:58AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) ("Nichi-Iko" or "Parent"
today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent" (NASDAQ:SGNT) at $21.75 per share, net to the holder in cash, without interest, less any applicable withholding taxes. The tender offer was effected by Nichi-Iko's wholly-owned subsidiary, Shepard Vision, Inc. (the "Purchaser".
SGNT: 21.76 (+0.03)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)
GlobeNewswire - Wed Aug 10, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company" (Nasdaq:SGNT) in the United States District Court for the Northern District of Illinois on behalf of current stock holders of Sagent, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act".
SGNT: 21.76 (+0.03)
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
BusinessWire - Tue Aug 09, 8:25AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) ("Nichi-Iko" or "Parent" and Shepard Vision, Inc. ("Purchaser" announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR", with respect to its proposed acquisition of Sagent Pharmaceuticals, Inc. ("Sagent"; Nasdaq: SGNT) expired effective August 8, 2016, at 11:59 p.m. (Eastern Daylight Time).
SGNT: 21.76 (+0.03)
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of $21.75 Net Per Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 01, 8:55AM CDT
Shepard Vision, Inc., a Delaware corporation (the "Purchaser" and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. (the "Parent", a joint stock corporation organized under the laws of Japan, today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent", a Delaware corporation (NASDAQ: SGNT), at a price of $21.75 per Share (the "Offer Price", net to the holder in cash, without interest, less any applicable withholding taxes (the "Offer".
SGNT: 21.76 (+0.03)
Generic Drugs Market in Japan between year 2015 to 2019 by Market Research Reports
M2 - Thu May 14, 6:40AM CDT
Our analyst researched the following companies as the key players in the Generic Drugs Market in Japan: Meiji Seika Pharma Co. Ltd., Nichi-Iko Pharmaceutical Co. Ltd., Nipro Pharma Corp., Sawai Pharmaceuticals Co. Ltd., Teva Pharmaceutical Industries Ltd. and Towa Pharmaceutical Co. Ltd.
TEVA: 50.48 (+0.12), GSK: 43.21 (+0.15)
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 29, 6:58AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) ("Nichi-Iko" or "Parent"
today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent" (NASDAQ:SGNT) at $21.75 per share, net to the holder in cash, without interest, less any applicable withholding taxes. The tender offer was effected by Nichi-Iko's wholly-owned subsidiary, Shepard Vision, Inc. (the "Purchaser". SGNT: 21.76 (+0.03)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)
GlobeNewswire - Wed Aug 10, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company"
(Nasdaq:SGNT) in the United States District Court for the Northern District of Illinois on behalf of current stock holders of Sagent, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act". SGNT: 21.76 (+0.03)
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
BusinessWire - Tue Aug 09, 8:25AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) ("Nichi-Iko" or "Parent"
and Shepard Vision, Inc. ("Purchaser" announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR", with respect to its proposed acquisition of Sagent Pharmaceuticals, Inc. ("Sagent"; Nasdaq: SGNT) expired effective August 8, 2016, at 11:59 p.m. (Eastern Daylight Time). SGNT: 21.76 (+0.03)
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of $21.75 Net Per Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 01, 8:55AM CDT
Shepard Vision, Inc., a Delaware corporation (the "Purchaser"
and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. (the "Parent", a joint stock corporation organized under the laws of Japan, today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent", a Delaware corporation (NASDAQ: SGNT), at a price of $21.75 per Share (the "Offer Price", net to the holder in cash, without interest, less any applicable withholding taxes (the "Offer". SGNT: 21.76 (+0.03)
Generic Drugs Market in Japan between year 2015 to 2019 by Market Research Reports
M2 - Thu May 14, 6:40AM CDT
Our analyst researched the following companies as the key players in the Generic Drugs Market in Japan: Meiji Seika Pharma Co. Ltd., Nichi-Iko Pharmaceutical Co. Ltd., Nipro Pharma Corp., Sawai Pharmaceuticals Co. Ltd., Teva Pharmaceutical Industries Ltd. and Towa Pharmaceutical Co. Ltd.
TEVA: 50.48 (+0.12), GSK: 43.21 (+0.15)
(0)
(0)Scroll down for more posts ▼